These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 29018164)

  • 1. Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca
    Diness JG; Skibsbye L; Simó-Vicens R; Santos JL; Lundegaard P; Citerni C; Sauter DRP; Bomholtz SH; Svendsen JH; Olesen SP; Sørensen US; Jespersen T; Grunnet M; Bentzen BH
    Circ Arrhythm Electrophysiol; 2017 Oct; 10(10):e005125. PubMed ID: 29018164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
    Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
    Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses.
    Haugaard MM; Hesselkilde EZ; Pehrson S; Carstensen H; Flethøj M; Præstegaard KF; Sørensen US; Diness JG; Grunnet M; Buhl R; Jespersen T
    Heart Rhythm; 2015 Apr; 12(4):825-35. PubMed ID: 25542425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog.
    Qi XY; Diness JG; Brundel BJ; Zhou XB; Naud P; Wu CT; Huang H; Harada M; Aflaki M; Dobrev D; Grunnet M; Nattel S
    Circulation; 2014 Jan; 129(4):430-40. PubMed ID: 24190961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.
    van Hunnik A; Lau DH; Zeemering S; Kuiper M; Verheule S; Schotten U
    Heart Rhythm; 2016 Apr; 13(4):964-72. PubMed ID: 26681610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation.
    Diness JG; Sørensen US; Nissen JD; Al-Shahib B; Jespersen T; Grunnet M; Hansen RS
    Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):380-90. PubMed ID: 20562443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
    Seyler C; Schweizer PA; Zitron E; Katus HA; Thomas D
    Biochem Biophys Res Commun; 2014 Aug; 451(3):415-20. PubMed ID: 25108155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The K
    Diness JG; Kirchhoff JE; Speerschneider T; Abildgaard L; Edvardsson N; Sørensen US; Grunnet M; Bentzen BH
    Front Pharmacol; 2020; 11():159. PubMed ID: 32180722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of SK-channels with AP14145 prevents atrial arrhythmogenic changes in a porcine model for obstructive respiratory events.
    Linz B; Hesselkilde EM; Skarsfeldt MA; Hertel JN; Sattler SM; Yan Y; Tfelt-Hansen J; Diness JG; Bentzen BH; Linz D; Jespersen T
    J Cardiovasc Electrophysiol; 2023 Jan; 34(1):126-134. PubMed ID: 36482155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs.
    Bechard J; Gibson JK; Killingsworth CR; Wheeler JJ; Schneidkraut MJ; Huang J; Ideker RE; McAfee DA
    J Cardiovasc Pharmacol; 2011 Mar; 57(3):302-7. PubMed ID: 21266917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria.
    van Hunnik A; Nasrallah H; Lau DH; Kuiper M; Verheule S; Schotten U
    Europace; 2018 Jan; 20(1):140-148. PubMed ID: 28449044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.
    Kirchhoff JE; Diness JG; Sheykhzade M; Grunnet M; Jespersen T
    Heart Rhythm; 2015 Feb; 12(2):409-18. PubMed ID: 25496982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The duration of pacing-induced atrial fibrillation is reduced in vivo by inhibition of small conductance Ca(2+)-activated K(+) channels.
    Skibsbye L; Diness JG; Sørensen US; Hansen RS; Grunnet M
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):672-81. PubMed ID: 21394037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vernakalant in an experimental model of pacing-induced heart failure: lack of proarrhythmia despite prolongation of repolarization.
    Frommeyer G; Schulze Grotthoff J; Fischer C; Bogossian H; Reinke F; Kochhäuser S; Dechering DG; Fehr M; Milberg P; Eckardt L
    J Card Fail; 2014 Oct; 20(10):786-792. PubMed ID: 25084217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria.
    Skibsbye L; Poulet C; Diness JG; Bentzen BH; Yuan L; Kappert U; Matschke K; Wettwer E; Ravens U; Grunnet M; Christ T; Jespersen T
    Cardiovasc Res; 2014 Jul; 103(1):156-67. PubMed ID: 24817686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiarrhythmic drugs on small conductance calcium - activated potassium channels.
    Simó-Vicens R; Sauter DRP; Grunnet M; Diness JG; Bentzen BH
    Eur J Pharmacol; 2017 May; 803():118-123. PubMed ID: 28322838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective termination of atrial fibrillation by SK channel inhibition is associated with a sudden organization of fibrillatory conduction.
    Gatta G; Sobota V; Citerni C; Diness JG; Sørensen US; Jespersen T; Bentzen BH; Zeemering S; Kuiper M; Verheule S; Schotten U; van Hunnik A
    Europace; 2021 Nov; 23(11):1847-1859. PubMed ID: 34080619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.